Enalapril: Difference between revisions
No edit summary |
No edit summary |
||
| Line 44: | Line 44: | ||
| P1S1S3 | | P1S1S3 | ||
|} | |} | ||
==Mechanism of Action == | |||
Enalapril is an inhibitor of angiotensin-I converting enzyme (ACE inhibitor). | |||
The beneficial effects of ACE inhibitors appear to result primarily from the suppression of the plasma renin-angiotensin-aldosterone system. Renin is synthesized by the kidneys and released into the circulation where it converts angiotensinogen to angiotensin-I. Angiotensin-I is then converted by angiotensin converting enzyme to angiotensin-II. Angiotensin-II is a potent vasoconstrictor responsible for arterial vasoconstriction and increased blood pressure, as well as for stimulation of the adrenal gland to secrete aldosterone. | |||
Inhibition of ACE results in decreased plasma angiotensin-II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. | |||
Enalapril is used in the treatment of hypertension and heart failure. It may also be given prophylactically to patients with asymptomatic left ventricular dysfunction to delay the onset of symptomatic heart failure, and has been used in patients with left ventricular dysfunction to reduce the incidence of coronary ischaemic events, including myocardial infarction. | |||
== Route of Administration == | |||
Enalapril is administered orally as enalapril maleate. | |||
Revision as of 22:49, 21 August 2022
Pronunciation
Enalapril 10mg
Enalapril 5mg
| Generic Name: | Enalapril |
|---|---|
| Class: | Cardiovascular Drug |
| Subclass: | ACE inhibitors |
| Legal Classification: | P1S1S3 |
Drug Names
| Generic Name 藥物化學名稱 | HA Code 藥物代碼 | Legal Classification法律藥物分類 |
|---|---|---|
| Enalapril Maleate Tablet 2.5mg | P1S1S3 | |
| Enalapril Maleate Tablet 5mg | ENAL02 | P1S1S3 |
| Enalapril Maleate Tablet 10mg | ENAL03 | P1S1S3 |
| Enalapril Maleate Tablet 20mg | ENAL01 | P1S1S3 |
Mechanism of Action
Enalapril is an inhibitor of angiotensin-I converting enzyme (ACE inhibitor). The beneficial effects of ACE inhibitors appear to result primarily from the suppression of the plasma renin-angiotensin-aldosterone system. Renin is synthesized by the kidneys and released into the circulation where it converts angiotensinogen to angiotensin-I. Angiotensin-I is then converted by angiotensin converting enzyme to angiotensin-II. Angiotensin-II is a potent vasoconstrictor responsible for arterial vasoconstriction and increased blood pressure, as well as for stimulation of the adrenal gland to secrete aldosterone. Inhibition of ACE results in decreased plasma angiotensin-II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. Enalapril is used in the treatment of hypertension and heart failure. It may also be given prophylactically to patients with asymptomatic left ventricular dysfunction to delay the onset of symptomatic heart failure, and has been used in patients with left ventricular dysfunction to reduce the incidence of coronary ischaemic events, including myocardial infarction.
Route of Administration
Enalapril is administered orally as enalapril maleate.
